NTLA - インテリア・セラピュ―ティクス (Intellia Therapeutics Inc.)

NTLAのニュース

   Intellia Therapeutics PT Lowered to $131 at Stifel  2023/01/06 13:37:06 Investing.com
https://www.investing.com/news/pro/intellia-therapeutics-pt-receives-investment-bank-analyst-rating-update-432SI-2974761
   Is Intellia Therapeutics Inc. (NASDAQ) Bullish Or Bearish In 2022?  2022/12/30 13:00:00 Stocks Register
Intellia Therapeutics Inc. (NASDAQ:NTLA) shares, rose in value on Thursday, 12/29/22, with the stock price up by 5.44% to the previous day’s close as strong demand from buyers drove the stock to $35.28. Actively observing the price movement in the last trading, the stock closed the session at $33.46, falling within a range of $33.93 … Is Intellia Therapeutics Inc. (NASDAQ) Bullish Or Bearish In 2022? Read More »
   Analysts Predict Intellia Therapeutics Inc. (NASDAQ: NTLA) To Loss -394.57% From Current Levels.  2022/12/26 20:00:00 Stocks Register
The trading price of Intellia Therapeutics Inc. (NASDAQ:NTLA) closed lower on Friday, December 23, closing at $34.98, -3.02% lower than its previous close. Traders who pay close attention to intraday price movement should know that it fluctuated between $34.47 and $35.92. In examining the 52-week price action we see that the stock hit a 52-week … Analysts Predict Intellia Therapeutics Inc. (NASDAQ: NTLA) To Loss -394.57% From Current Levels. Read More »
   Intellia Therapeutics Inc. (NASDAQ: NTLA): Can A Stock Be -69.49% Lower Year-To-Date And Still Be A Loser?  2022/12/23 20:00:00 Marketing Sentinel
Intellia Therapeutics Inc. (NASDAQ:NTLA)’s traded shares stood at 0.35 million during the latest session, with the company’s beta value hitting 1.91. At the last check today, the stock’s price was $34.98, to imply a decrease of -3.02% or -$1.09 in intraday trading. The NTLA share’s 52-week high remains $129.13, putting it -269.15% down since that … Intellia Therapeutics Inc. (NASDAQ: NTLA): Can A Stock Be -69.49% Lower Year-To-Date And Still Be A Loser? Read More »
   What Can Intellia Therapeutics Inc. (NASDAQ: NTLA) Expect In 2022?  2022/12/22 15:30:00 Stocks Register
Intellia Therapeutics Inc. (NASDAQ:NTLA) price on Wednesday, December 21, rose 0.50% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $36.21. A look at the stock’s price movement, the close in the last trading session was $36.03, moving within a range at $35.58 and $37.01. The beta value … What Can Intellia Therapeutics Inc. (NASDAQ: NTLA) Expect In 2022? Read More »
   Intellia wins FDA orphan drug designation for genome editing therapy for severe swelling  2022/09/01 20:19:56 Seeking Alpha
Intellia Therapeutics (NTLA) on Thursday said the U.S. FDA had granted an orphan drug designation to the company''s genome editing candidate NTLA-2002
   Intellia Therapeutics Inc. (NASDAQ: NTLA) Drops -220.76% From Highs, What Happens Next?  2022/08/20 16:00:00 Marketing Sentinel
Intellia Therapeutics Inc. (NASDAQ:NTLA)’s traded shares stood at 0.83 million during the last session, with the company’s beta value hitting 2.01. At the close of trading, the stock’s price was $56.30, to imply a decrease of -5.33% or -$3.17 in intraday trading. The NTLA share’s 52-week high remains $180.59, putting it -220.76% down since that … Intellia Therapeutics Inc. (NASDAQ: NTLA) Drops -220.76% From Highs, What Happens Next? Read More »
   7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher  2022/08/17 13:29:22 InvestorPlace
Monkeypox stocks, our topic for today, have had a mostly mixed performance so far in 2022. It is likely, however, that they could benefit from the similar tailwinds enjoyed by companies, such as Pfizer (NYSE: PFE ), BioNTech (NASDAQ: BNTX ), and Moderna (NASDAQ: MRNA ), which have developed the Covid-19 vaccines that have now become household names. Monkeypox is a smallpox-like disease caused by the monkeypox virus. Both viruses share the same genus: Orthopoxvirus . Originally relegated to certain central and western African countries, the disease has spread to some 31,000 people globally. There are around 10,000 cases stateside. Yet, the majority of monkeypox cases are relatively mild. The disease’s relative mildness aside, fears of a possible Covid-like monkeypox pandemic have alleviated some of the recent woes afflicting the biotech industry. Not entirely of course, as the NASDAQ Biotechnology Index, for example, is still down around 10% year to date (YTD). Meanwhile, the broader NASDAQ Composite has fallen almost 16% over the same period.
   Intellia Therapeutics Inc. (NASDAQ:NTLA) Share Price Rebounds 43.48% From The Lows – But Can It Keep Going?  2022/08/12 11:00:00 Marketing Sentinel
In last trading session, Intellia Therapeutics Inc. (NASDAQ:NTLA) saw 1.6 million shares changing hands with its beta currently measuring 2.01. Company’s recent per share price level of $65.60 trading at -$0.94 or -1.41% at ring of the bell on the day assigns it a market valuation of $5.14B. That closing price of NTLA’s stock is … Intellia Therapeutics Inc. (NASDAQ:NTLA) Share Price Rebounds 43.48% From The Lows – But Can It Keep Going? Read More »
   7 Stock Price Predictions That Are Actually Worth Listening To  2022/08/12 10:10:04 InvestorPlace
Generally, Wall Street stock price predictions are hardly the best source of investing ideas that have the most upside. Investors should interpret stocks that analysts claim have the most upside carefully. Often, either the analyst is too optimistic about the company’s fair value or the stock market is wrong. Investors may pick stocks with the most promising price predictions by reviewing their stock scores. As difficult as it is to make stock price predictions based on the numbers alone, sometimes those numbers indicate a definite price discrepancy. In what follows, we’ll take a look at stock price predictions for companies that seem preternaturally correct. APP AppLovin $34.46 BHC Bausch Health $6.20 APPS Digital Turbine $22.91 FTCH Farfetch $9.90 NTLA Intellia Therapeutics $65.60 SE Sea $88.58 WBD Warner Bros. Discovery $13.68 AppLovin (APP) Source: T. Schneider / Shutterstock.com AppLovin (NASDAQ: APP ) acquired MoPub. In the last quarter, it completed migrating it into its MAX platform.
   Intellia Therapeutics, Inc. (NTLA) CEO John Leonard on Q2 2022 Results - Earnings Call Transcript  2022/08/04 16:57:12 Seeking Alpha
Intellia Therapeutics, Inc. (NASDAQ:NASDAQ:NTLA) Q2 2022 Results Earnings Conference Call August 4, 2022, 08:00 AM ET Company Participants Ian Karp - Senior Vice President , Investor…
   Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety Questioned  2022/08/04 16:39:57 Investor''s Business Daily
A gene-editing treatment from Intellia led to elevated liver enzymes in one patient with polyneuropathy, prodding NTLA stock to topple.
   Why Intellia Therapeutics Stock Is Sinking Today  2022/08/04 15:31:47 The Motley Fool
Investors are reacting negatively to the company''s Q2 update.
   Intellia Therapeutics down 12% following bottom line Q2 earnings miss (NASDAQ:NTLA)  2022/08/04 14:29:59 Seeking Alpha
Intellia Therapeutics (NTLA) is down 12% in Thursday morning trading after it missed analyst estimates on Q2 2022 EPS.
   BABA Stock Jumps as Alibaba Beats on Earnings  2022/08/04 14:20:57 InvestorPlace
Source: Kevin Chen Photography / Shutterstock.com Alibaba (NYSE: BABA ) stock is gaining on Thursday following the release of the Chinese e-commerce company’s earnings report for the second quarter of 2022. The good news for BABA stock starts with the company’s adjusted earnings per share of $1.75 . That’s a positive considering Wall Street’s estimate of $1.53 for the quarter. However, it’s a 29% drop from the $2.57 per share reported during the same period of the year prior. In addition to that, Alibaba reported revenue of $30.69 billion for the second quarter of the year. This is better than the $29.97 billion in revenue that analysts were expecting. Revenue is mostly stable compared to last year. That’s due to a 1% drop in commerce business that’s offset by a 10% growth in its Cloud segment. 7 Blue-Chip Stocks to Buy Before the Bull Market Returns BABA Stock: Covid-10 Negativly Affected Earnings According to Alibaba, the decline in commerce revenue is the result of the Covid-19 pandemic.

calendar